CAS: 106803-22-9

Deethylindanomycin, a polyether antibiotic from S. setonii, combats Gram-positive bacteria and in vitro coccidia; ionophore selective for K+ ions.

Omomycin is a novel antibiotic, specifically a macrolide, which is derived from microbial sources, primarily soil-dwelling actinomycetes. Its mode of action involves inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit. This interaction prevents the translocation of peptides during translation, thereby halting bacterial growth and proliferation. The primary uses and applications of Omomycin are in the treatment of multi-drug resistant bacterial infections, particularly those caused by Gram-positive pathogens such as Staphylococcus aureus and Streptococcus pneumoniae. It has shown efficacy in overcoming resistance associated with traditional antibiotics and has been studied for its potential role in addressing healthcare-associated infections. The ongoing development and research into Omomycin focus on its pharmacokinetics, dosing regimens, and long-term safety profile in various clinical settings.